医药界“泡泡玛特”:递表港交所

药事纵横
Nov 02

声明:因水平有限,错误不可避免,或有些信息非最及时,欢迎留言指出。本文仅作医疗健康相关药物介绍,非治疗方案推荐(若涉及);本文不构成任何投资建议。10月31日,中国生物科技企业新桥生物-B正式向港交所主板提交上市申请书,联席保荐人由中信证券(29.680, -0.62, -2.05%)与高盛共同担任,公司暂未披露拟发行股数及募资规模。10月29日,新桥生物宣布,公司已完成名称变更,由“I-Mab”...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10